Abstract
The damage of the novel Coronavirus disease (COVID-19) is reaching unprecedented scales. There are numerous classical epidemiology models trying to quantify epidemiology metrics. Usually, to forecast the epidemics, these classical approaches need parameter estimations, such as the contagion rate or the basic reproduction number. Here, we propose a data-driven, parameter-free approach to access the fragility and systemic risk of epidemic networks by studying the Forman-Ricci curvature. Network curvature has been used successfully to forecast risk in financial networks and we suggest that those results can be translated for COVID-19 epidemic time series as well. We first show that our hypothesis is true in a toy-model of epidemic time series with delays, which generates epidemic networks. By doing so, we are able to verify that the Forman-Ricci curvature can be a parameter-free estimate for the fragility and risk of the network at each stage of the simulated pandemic. On this basis, we then compute the Forman-Ricci curvature for real epidemic networks built from epidemic time series available from the World Health Organization (WHO). The Forman-Ricci curvature allow us to detect early warning signs of the emergence of the pandemic. The advantage of the method lies in providing an early geometrical data marker for epidemics, without the need of parameter estimation and stochastic modeling. The strategy above, together with other data-driven tools for investigating epidemic network dynamics, can be readily implemented on a daily basis to quickly estimate the growth, risk and fragility of real COVID-19 epidemic networks at different scales.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partially funded by INES 2.0, FACEPE grants PRONEX APQ-0602-1.05/14, APQ 0388-1.03/14 and APQ-0399-1.03/17, CAPES grant 88887.136410/2017-00, and CNPq grant 465614/2014-0
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is freely available at the World Health Organization (WHO)